Axcella is designing and developing AXA Candidates, compositions of endogenous metabolic modulators, or EMMs, engineered in distinct ratios, designed to target and maximize the fundamental role that EMMs play in regulating multiple metabolic functions. Axcella’s AXA Candidates are generated from its proprietary, human-focused AXA Development Platform. Axcella believes its expertise and capabilities in EMMs position it to become a preeminent biotechnology company reprogramming metabolism to address a diverse set of complex diseases and support health. Axcella’s AXA Development Platform has already produced a pipeline of product candidates in programs targeting liver, muscle and blood. Axcella was founded by Flagship Pioneering.
Copyright West LLC. Minimum 15 minutes delayed.
Initiated a Non-IND, IRB-Approved Clinical Study for AXA1957 in adolescent subjects with NAFLD Announced the publication in Frontiers of data describing attenuation of muscle atrophy observed with AXA2678 in short-term muscle disuse study Finished the second quarter with $117.9 million in cash and
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 7, 2019-- Axcella Health (Nasdaq: AXLA), a biotechnology company pioneering the research and development of novel multifactorial interventions to address dysregulated metabolism and support health, today announced that Bill Hinshaw , President and CEO, will
Administration of AXA2678 was well-tolerated with no significant safety issues over 28 days AXA2678 attenuated muscle mass loss and reduced intramuscular fat accumulation in healthy young male study subjects Data supports the ability to use endogenous metabolic modulators to address dysregulated